Genmab — November 2017
-
Er det ikke ved at være lidt træls med al den AB snak.. - Mig bekendt, står AB for et x antal brokere. Som af en eller anden årsag, må være anonyme.... Men i en aktie som Genmab, kan man da ikke tolke noget som helst, ved at se på, hvad AB gør og ikke gør?.... Mht. fastsættelse af en fair kurs på Genmab. - Det er jo helt umuligt.... Men i og med at den i 1400+ igennem flere måneder, må man gå ud fra at denne kurs var fri for eufori etc. Så jeg vil mene at kurs 1400 virker mere rimelig end 1200
-
This growth can be largely attributed to the expansion
of existing therapies such as the PD-1/PD-L1 inhibitors Opdivo and Keytruda and J&J’s Darzalex, as well as the launch of novel therapies, such as Sano /Regeron’s Dupixent in atopic dermatitis and Roche’s Ocrevus in multiple sclerosis. CAR-T therapies continue to generate interest in oncology although the recent safety issues have partially dampened any short term excitement.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind